Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma | Zendy

Sattva S. Neelapu | Zendy; Caron A. Jacobson | Zendy; Olalekan O. Oluwole | Zendy; Javier Muñoz | Zendy; Abhinav Deol | Zendy; David B. Miklos | Zendy; Nancy L. Bartlett | Zendy; Ira Braunschweig | Zendy; Yizhou Jiang | Zendy; Jenny J. Kim | Zendy; Lianqing Zheng | Zendy; John M. Rossi | Zendy; Frederick L. Locke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Author(s) -

Sattva S. Neelapu,

Caron A. Jacobson,

Olalekan O. Oluwole,

Javier Muñoz,

Abhinav Deol,

David B. Miklos,

Nancy L. Bartlett,

Ira Braunschweig,

Yizhou Jiang,

Jenny J. Kim,

Lianqing Zheng,

John M. Rossi,

Frederick L. Locke

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019004162

Subject(s) - medicine , chimeric antigen receptor , refractory (planetary science) , lymphoma , oncology , immunology , immunotherapy , cancer , biology , astrobiology

Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have similar rates of complete response and durable response at 2 years, but higher rates of neurological toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research